These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8251768)

  • 1. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
    Ward RL; Morgan G; Dalley D; Kelly PJ
    Bone Miner; 1993 Aug; 22(2):87-94. PubMed ID: 8251768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
    Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
    Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women.
    Grey AB; Stapleton JP; Evans MC; Tatnell MA; Ames RW; Reid IR
    Am J Med; 1995 Dec; 99(6):636-41. PubMed ID: 7503087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
    Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
    J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
    J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
    Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
    Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
    Zidan J; Keidar Z; Basher W; Israel O
    Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer.
    Resch A; Biber E; Seifert M; Resch H
    Acta Oncol; 1998; 37(7-8):661-4. PubMed ID: 10050983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
    Rymer J; Robinson J; Fogelman I
    Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
    Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can biochemical markers predict bone loss at the hip and spine?: a 4-year prospective study of 141 early postmenopausal women.
    Keen RW; Nguyen T; Sobnack R; Perry LA; Thompson PW; Spector TD
    Osteoporos Int; 1996; 6(5):399-406. PubMed ID: 8931035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
    Kalder M; Hans D; Kyvernitakis I; Lamy O; Bauer M; Hadji P
    J Clin Densitom; 2014; 17(1):66-71. PubMed ID: 23562130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.